| Today’s Big NewsJul 11, 2024 |
|
September 30- October 1, 2024 | Boston, MA Join the Fierce Biotech Summit to explore biotech's recovery and future. This two-day event features leaders discussing biotech IPOs, cell therapy, regulatory challenges, and strategic innovations. Connect with experts and gain valuable industry insights. Grab your pass today! 
|
|
| By Nick Paul Taylor Pfizer has dragged the oral GLP-1 candidate danuglipron back from the brink. Months after dropping one version of the asset, the Big Pharma has vowed to advance a once-daily, modified-release formulation on the strength of “encouraging pharmacokinetic data.” |
|
|
|
By James Waldron An R&D center in San Diego is the latest area to be impacted by Novartis’ ongoing global development restructure, the company has confirmed. |
By Annalee Armstrong The obesity game is only in its early innings, and the future market will be defined by who can ease administration of the medicines, according to a new report from Evaluate. |
By Helen Floersh Young adult mice with a genetic form of progressive deafness can hear again after being treated with an experimental CRISPR gene therapy that its creators hope to eventually use in humans. |
By James Waldron Ipsen is back with its second antibody-drug conjugate deal of the year, this time signing a $1 billion biobucks pact with Foreseen Biotechnology for a preclinical solid tumor candidate. |
By Helen Floersh Clinical trial geography has undergone a major shift in the past five years, with China’s share of the world’s trials jumping nearly 60% amid declines in Europe, according to a report released July 10 by the IQVIA Institute. |
By Zoey Becker Novo Nordisk's Ozempic is slated to take over No.1, while Merck's Keytruda falls to No.9 on Evaluate's predicted rankings of top drugs by 2030 sales. |
By Kevin Dunleavy The FDA has slowed the roll for Novo Nordisk, rejecting its once-a-week insulin icodec for patients with Type 1 and Type 2 diabetes. In a complete response letter, the U.S. regulator cited manufacturing issues, which the company said it does not expect to remedy by the end of this year. |
By Dave Muoio Strategic dealmaking that leverages IP or doubles down on high-growth markets was front and center in the second quarter of 2024, per a new Kaufman Hall report. A concurrent monthly report from the advisory firm also outlined signs of stabilization within the hospital sector. |
Fierce podcasts Don’t miss an episode |
| In today’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest biopharma acquisitions in recent years. |
|
|---|
|
|
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Whitepaper In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
